On February 22, 2019 Cerus Corporation (Nasdaq:CERS) reported that the Company will participate in two upcoming investor conferences (Press release, Cerus, FEB 22, 2019, View Source [SID1234533602]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Obi Greenman, Cerus’ president and chief executive officer is scheduled to attend BTIG’s Annual Healthcare Conference in Snowbird Utah on Wednesday, February 27, 2019.
Obi Greenman and Kevin Green, Cerus’ vice president finance and chief financial officer, are scheduled to present a corporate update at Cowen’s 39th Annual Healthcare Conference in Boston, Massachusetts on Tuesday, March 12, 2019 at 10:00 a.m. ET.
A live webcast of the presentation from Cowen’s 39th Annual Healthcare Conference will be available on the Investor Relations page of the Cerus web site at View Source A replay will be available for approximately two weeks following the completion of the event

On February 22, 2019 Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, reported that Jigar Raythatha, CEO, will present at the SVB Leerink Global Healthcare Conference in New York at 9:00 AM EST on Friday, March 1, and at the Cowen and Company Health Care Conference in Boston at 11:20 AM EDT on Monday, March 11 (Press release, Constellation Pharmaceuticals, FEB 22, 2019, View Source [SID1234533603]). Live audio webcasts of these presentations and archives for replay will be available on the Investor Relations section of Constellation’s website at View Source The audio webcast replays will be available for 90 days following the live presentation.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On February 22, 2019 Polaris Group reported that Shaw Chen, M.D., Ph.D. has been appointed as the Interim Chief Executive Officer (Press release, Polaris Pharmaceuticals, FEB 22, 2019, View Source [SID1234534439]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

After more than 26 years with the FDA where he was the Deputy Director in the Office of Drug Evaluation, Center for Drug Evaluation and Research, Dr. Chen brings a wealth of expertise and institutional knowledge to Polaris Group. With his experience in FDA regulatory processes, Dr. Chen will be an invaluable asset as Polaris Group works to streamline the clinical development of its lead anti-cancer compound, ADI-PEG 20.

"The insight into the FDA that Dr. Chen has will be extremely valuable as we move forward with clinical investigations of ADI-PEG 20," said John Bomalaski, Executive Vice President of Medical Affairs at Polaris. "We are thrilled to work with him while we continue to search for a permanent CEO."

About ADI‑PEG 20

ADI‑PEG 20 is a biologic being developed by Polaris Group to treat cancers carrying a major metabolic defect that renders them unable to internally synthesize arginine. Because arginine is essential for protein synthesis and survival of cells, these cancer cells become dependent upon the external supply of arginine to survive and grow. ADI‑PEG 20 is designed to deplete the external supply of arginine, causing arginine-dependent cancer cells to die while leaving the patient’s normal cells unharmed. Multiple cancers have been reported to have a high degree of arginine-dependency and can potentially be treated with ADI‑PEG 20.

On February 22, 2019 BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer, reported that the company will present at the 8th Annual SVB Leerink Global Healthcare Conference in New York, NY (Press release, BeiGene, FEB 22, 2019, View Source;p=irol-newsArticle&ID=2388559 [SID1234533584]). The presentation is scheduled for 10:00 a.m. EST on Friday, March 1st, 2019.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast can be accessed from the investors section of BeiGene’s website at View Source An archived replay will be available for 90 days following the event.

On February 22, 2019 FibroGen, Inc. (NASDAQ: FGEN), a leading biopharmaceutical company discovering and developing a pipeline of first-in-class therapeutics, reported that it will report fourth quarter and full year 2018 financial results on Wednesday, February 27, 2019 after market close, and will host a conference call to discuss financial results and provide a business update at 5:00 p.m. ET (2:00 p.m. PT) (Press release, FibroGen, FEB 22, 2019, View Source;p=irol-newsArticle&ID=2388639 [SID1234533605]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference Call and Audio Webcast
Interested parties may access a live audio webcast of the conference call via the investor section of the FibroGen website, www.fibrogen.com. It is recommended that listeners access the website 15 minutes prior to the start of the call to download and install any necessary audio software. A replay of the webcast will be available shortly after the call for a period of two weeks. To access the replay, please dial (888) 843-7419 (domestic) or (630) 652-3042 (international), and use passcode 48309188#.

Dial-In Information
Live (U.S./Canada): (888) 771-4371
Live (International): (847) 585-4405
Confirmation number: 48309188